A Phase Ib/ II Study of Sorafenib and Pembrolizumab in Advanced Hepatocellular Cancer (HCC)
Latest Information Update: 10 Jun 2025
At a glance
- Drugs Pembrolizumab (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
Most Recent Events
- 04 Jun 2025 Planned End Date changed from 7 May 2025 to 7 Dec 2025.
- 28 Feb 2025 Planned End Date changed from 7 Dec 2024 to 7 May 2025.
- 03 Jul 2024 Planned End Date changed from 7 Jun 2024 to 7 Dec 2024.